Hematopoietic stem cell transplantation for multiple sclerosis: Improving understanding and addressing misconceptions

Area of Science:

• Neurology
• Immunology
• Hematology

Background:

• Autologous hematopoietic stem cell transplantation (HSCT) involves immunosuppression followed by stem cell infusion to restore blood cell production.
• Nonmyeloablative HSCT regimens are safer for multiple sclerosis (MS) than traditional myeloablative approaches used in cancer treatment.

Purpose of the Study:

• To evaluate the efficacy and safety of autologous HSCT for multiple sclerosis (MS).
• To compare HSCT outcomes against current disease-modifying therapies (DMTs) for MS.

Main Methods:

• Administration of a short immunosuppressive regimen (4-6 days) followed by autologous stem cell infusion.
• Patient selection and specific regimen protocols are critical determinants of HSCT toxicity and efficacy.

Main Results:

• HSCT is most effective for the inflammatory phase of MS, including relapsing-remitting MS and active secondary progressive MS.
• A Phase III randomized trial and meta-analyses show HSCT superiority over contemporary DMTs, including natalizumab.
• HSCT leads to sustained, drug-free improvements in neurological disability and quality of life in most patients.

Conclusions:

• Autologous HSCT represents a significant advancement in MS treatment, offering long-term benefits beyond conventional therapies.
• The procedure's effectiveness is stage-dependent, highlighting its role in managing active inflammatory MS.
• HSCT provides a valuable therapeutic option for MS patients, demonstrating superior long-term outcomes compared to DMTs.